MS stem cell transplant study: tracking immune reboot after treatment
NCT ID NCT07635693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 20 adults with multiple sclerosis who are already scheduled for a stem cell transplant. Researchers will measure levels of an immune-suppressing drug called ATLG and track how the immune system rebuilds itself afterward. The goal is to learn more about immune recovery and viral infections, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATLG (anti-T-lymphocyte globulin)
- What this could lead to
- If successful, this study could help doctors better understand how the immune system recovers after stem cell transplant in MS, potentially improving future treatment protocols.
- What could go wrong
- This is a small observational study, not a treatment trial. It will not directly test whether ATLG or the transplant works for MS, so results may not change current care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATLG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Ospedale San Raffaele
RECRUITINGMilan, Italy, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?